Clinical Trials Browser

Phase 2 × INDUSTRY × 3-Iodobenzylguanidine × Clear all

NCT03561259 2023-02-16

OPTIMUM

Phase 2 Unknown

Neoplasms, Neuroblastoma, Neuroectodermal Tumors

NCT00874614 2020-02-20

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Phase 2 Unknown

74 enrolled 10 charts 1 FDA

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors